Piper Sandler maintains Guardant Health at Overweight, lowers price target to $190 from $193
Piper Sandler kept its Overweight rating on Guardant Health but reduced its price target to $190 from $193, suggesting a 19.7% upside from the Nov 9 close of $158.79. Recent analyst notes have price targets ranging from $200 to $210.
How this was made

The 30-second read
Why it matters
The analyst downgrade reflects a slight shift in valuation but does not indicate a major change in fundamentals.
Market read
Small but actionable for traders monitoring analyst updates on biotech stocks.
What to watch
Recent trial data and partnership announcements could offset the modest target reduction.
Background
Guardant Health is a liquid biopsy company whose stock is closely watched after recent trial results.
Ticker impact
Piper Sandler lowered Guardant Health's price target to $190 from $193.
likely slight downward pressure as the market prices in the lower target
A 1.6% target reduction is modest but may prompt short‑term sellers.
Market effects
Minor impact on liquid biopsy/diagnostics sector as analysts adjust expectations.
Limited to US biotech investors.
Low global relevance.
Counterpoint
Target cut may be overly cautious; upside potential remains if upcoming data beats expectations.
Key entities
- AnalystPiper Sandler
Equity research firm that issued the target cut.
- CompanyGuardant Health
US‑listed liquid biopsy firm (ticker GH).
